DNER and acute myeloid leukemia: Based on these observations, clinical trials of a number of BET inhibitors in AML, lymphoma and solid tumors were initiated including FT1101 (NCT02543879), MK8628 (NCT02698189), RO6870810 (NCT02308761), GSK525762 (NCT01943851, EudraCT 2013-000445-39), ABBV-744 (NCT03360006), ABBV-075 (NCT02391480), CPI-0610 (NCT02158858), and INCB054329 (NCT02431260) (Table 1).